Biocryst Pharmaceuticals Inc (BCRX) Stock
Key stats
- Market cap
- $1.97B
- Price / Earnings ratio
- -5.4x
- EPS (TTM)
- -$1.35
- Volume
- Loading
- 52-week high
- $11.22
- 52-week low
- $6.23
Source: third-party data provider, as of November 13, 2026
Compare with BCRX
Recent news

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
BCRX

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BCRX

BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BCRX

4 Biotech Stocks to Watch as Potential Takeover Targets
4 Biotech Stocks to Watch as Potential Takeover Targets
BCRX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 41.27
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.13
- MACD histogram
- -0.04
- SMA 50
- $8.33
- Price below SMA 50
- EMA 50
- $8.34
- Price below EMA 50
- SMA 200
- $8.79
- Price below SMA 200
- EMA 200
- $8.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.09 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Wall Street Analysts See a 137.91% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
BCRX

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
BCRX

BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BioCryst Eyes $1B Rare-Disease Future Through External Innovation
BCRX

4 Biotech Stocks to Watch as Potential Takeover Targets
4 Biotech Stocks to Watch as Potential Takeover Targets
BCRX

BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
BCRX Stock Heads For Fifth Straight Day In The Red – RBC Capital Says BioCryst Faces A ‘Challenging Near-Term Outlook’
BCRX

BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
BCRX Stock Posts Worst Day In Over 6 Months After PHVS Trial Win In Rare Swelling Disease
BCRX

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
BCRX

Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
BCRX

BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
BCRX

Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
BCRX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Charles K. Gayer | CEO, President & Director | 1971 |
| Mr. Babar Ghias | CFO & Head of Corporate Development | 1979 |
| Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 1966 |
| Mr. John Ruesch | Chief Technical Operations Officer | — |
| Dr. David W. Jenkins M.A., Ph.D. | Chief Scientific Officer | — |
| Nick Wilder | Manager of Investor Relations | — |
| Ms. Stephanie Angelini | Chief People Officer & Communications Officer | — |
| Dr. William P. Sheridan MBBS | Chief Development Officer | 1955 |
| Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer | 1953 |
| Ms. Jinky Ang Rosselli | Chief Data Innovation Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.27
- MACD 12/26/9
- -0.17
- EMA 9 of MACD
- -0.13
- MACD histogram
- -0.04
- SMA 50
- $8.33
- Price below SMA 50
- EMA 50
- $8.34
- Price below EMA 50
- SMA 200
- $8.79
- Price below SMA 200
- EMA 200
- $8.43
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.00
- Average
- $14.25
- High
- $17.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +1.6 | +22.9 | ||||||||||
| 2022 | +9.8 | +8.3 | -3.3 | -44.0 | -3.0 | +12.1 | +1.7 | +28.2 | -10.6 | +4.3 | +12.6 | -11.4 |
| 2023 | -7.9 | -15.9 | -5.5 | -9.1 | +10.1 | -16.1 | +4.8 | +2.0 | -2.7 | -18.9 | +2.6 | -2.6 |
| 2024 | -12.7 | +6.6 | -9.6 | -18.2 | +41.4 | -9.0 | +9.1 | +22.2 | -7.9 | +8.5 | -11.0 | +1.9 |
| 2025 | +0.9 | +13.0 | -12.2 | +22.1 | +23.4 | -16.5 | -9.6 | +4.5 | -8.4 | -0.7 | +4.7 | +9.4 |
| 2026 | -12.3 | +32.0 | +10.3 | -2.3 | -3.0 | +16.7 | -6.9 | +10.1 | -16.0 | +4.3 | -7.3 |



